In a report released today, Iain Simpson from Barclays maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...

In a report released today, Guillaume Delmas from UBS maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...

Haleon is teaming up with the University of Sydney to launch a five-year fellowship to research the efficacy of dietary supplements for ...

Futura Medical, the consumer healthcare company behind Eroxon, announced on Monday that a $5m milestone payment had been ...

Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, both of whom expressed interest in supporting the activist investor's ...

Haleon plc (LSE/NYSE: HLN), a global consumer health company, disclosed today that Alan Stewart has resigned from its board of directors. Stewart's departure was effective as of Sunday ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Goldman Sachs raises AstraZeneca price target to 16,046 (15,914) pence - 'buy' Barclays raises Standard Chartered price target to 890 (850) pence - 'equal weight' Barclays raises Harbour Energy price ...

The acquired portfolio includes Nicotinell, also known as Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada.